Antonia Ridolfi
About
Antonia Ridolfi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, Antonia Ridolfi has authored 51 papers receiving a total of 735 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 29 papers in Pulmonary and Respiratory Medicine and 10 papers in Molecular Biology. Recurrent topics in Antonia Ridolfi's work include Advanced Breast Cancer Therapies (25 papers), Cancer Treatment and Pharmacology (12 papers) and HER2/EGFR in Cancer Research (11 papers). Antonia Ridolfi is often cited by papers focused on Advanced Breast Cancer Therapies (25 papers), Cancer Treatment and Pharmacology (12 papers) and HER2/EGFR in Cancer Research (11 papers). Antonia Ridolfi collaborates with scholars based in France, United States and Switzerland. Antonia Ridolfi's co-authors include David Neal Franz, Stephen Evans, Ruth Gilbert, Irwin Nazareth, Irene Petersen, J.C. Kingswood, Noah Berkowitz, Hope S. Rugo, Maurizio Voi and Е. Д. Белоусова and has published in prestigious journals such as Journal of Clinical Oncology, Neurology and Cancer.
In The Last Decade
Antonia Ridolfi
49 papers receiving 725 citations
Peers
Antonia Ridolfi
Toby Silverman United States
Heinz Tüchler Austria
Peter K. H. Lau Australia
A.R. Abdul Razak Canada
Jacques Raphael Canada
Fabiano Sandrini United States
N.S. Russell Netherlands
Agathe Bajard France
Rafał Stec Poland
Hélène Caillon France
Citations per year, relative to Antonia Ridolfi Antonia Ridolfi (= 1×)
peers
Toby Silverman
Countries citing papers authored by Antonia Ridolfi
Since
Specialization
Citations
This map shows the geographic impact of Antonia Ridolfi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antonia Ridolfi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antonia Ridolfi more than expected).
Fields of papers citing papers by Antonia Ridolfi
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Antonia Ridolfi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antonia Ridolfi. The network helps show where Antonia Ridolfi may publish in the future.
Co-authorship network of co-authors of Antonia Ridolfi
This figure shows the co-authorship network connecting the top 25 collaborators of Antonia Ridolfi. A scholar is included among the top collaborators of Antonia Ridolfi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antonia Ridolfi. Antonia Ridolfi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Dyachkova, Yulia, Cornelia Dunger‐Baldauf, Nathalie Barbier, et al.. (2024). Do You Want to Stay Single? Considerations on Single‐Arm Trials in Drug Development and the Postregulatory Space. Pharmaceutical Statistics. 23(6). 1206–1217.
2.
Burris, Howard A., Arlene Chan, Aditya Bardia, et al.. (2021). Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer. British Journal of Cancer. 125(5). 679–686.
3.
Canaud, Guillaume, et al.. (2021). LBA23 EPIK-P1: Retrospective chart review study of patients (pts) with PIK3CA-related Overgrowth Spectrum (PROS) who have received alpelisib (ALP) as part of a compassionate use programme. Annals of Oncology. 32. S1297–S1297.
4.
Fasching, Peter A., J. Thaddeus Beck, Arlene Chan, et al.. (2020). Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study. The Breast. 54. 148–154.
5.
Lu, Yen‐Shen, J.M.Y. Chiu, Mario Airoldi, et al.. (2020). 301P Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for alpelisib (ALP)-induced hyperglycemia: A report of 6 cases from SOLAR-1. Annals of Oncology. 31. S363–S363.
6.
Turner, Simon, Stephen Chia, Hemanth Kanakamedala, et al.. (2020). 309P Real-world effectiveness of alpelisib (ALP) + fulvestrant (FUL) compared with standard treatment among patients (Pts) with hormone-receptor positive (HR+) human epidermal growth factor receptor-2 negative (HER2–) PIK3CA-mutated (Mut) advanced breast cancer (ABC). Annals of Oncology. 31. S366–S366.
7.
Ciruelos, Eva, et al.. (2020). 163P Population-adjusted comparison of SOLAR-1 and BOLERO-2: PFS with second-line alpelisib + fulvestrant vs everolimus + exemestane in postmenopausal pts with PIK3CA-mut hormone-receptor positive (HR+) human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer (ABC). Annals of Oncology. 31. S74–S74.
8.
Yao, James C., Do‐Youn Oh, Jiaming Qian, et al.. (2019). <p>Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study</p>. OncoTargets and Therapy. Volume 12. 1717–1728.
9.
Lerner, S., et al.. (2019). <p>Maximum Medical Therapy: Brinzolamide/Brimonidine And Travoprost/Timolol Fixed-Dose Combinations In Glaucoma And Ocular Hypertension</p>. Clinical ophthalmology. Volume 13. 2411–2419.
10.
Loibl, Sibylle, Pierfranco Conté, Mario Campone, et al.. (2019). Response rate by geographic region in patients with hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer from the SOLAR-1 trial. Annals of Oncology. 30. iii48–iii49.
11.
Tripathy, Debu, G. N. Hortobágyi, Arlene Chan, et al.. (2019). Pooled efficacy analysis of first-line ribociclib (RIB) plus endocrine therapy (ET) in HR+/HER2: Advanced breast cancer (ABC). Annals of Oncology. 30. iii49–iii50.
12.
Franz, David Neal, John A. Lawson, Zühal Yapıcı, et al.. (2018). Efficacy and Safety of Everolimus Based on Prior and Concomitant Antiepileptic Drugs in Patients with Tuberous Sclerosis Complex (TSC)-Associated Treatment-Refractory Seizures: A Subanalysis of the Phase 3 EXIST-3 Study (S9.007). Neurology. 90(15_supplement).
13.
Curatolo, Paolo, David Neal Franz, John A. Lawson, et al.. (2018). Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial. The Lancet Child & Adolescent Health. 2(7). 495–504.
14.
Bissler, John J., David Neal Franz, Michael Frost, et al.. (2017). The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma. Pediatric Nephrology. 33(1). 101–109.
15.
Yao, James C., Nicola Fazio, Roberto Buzzoni, et al.. (2016). ORAL02.02: Efficacy and Safety of Everolimus in Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Lung: RADIANT-4 Subgroup Analysis. Journal of Thoracic Oncology. 11(11). S253–S253.
16.
Royce, Melanie, Mustafa Özgüroğlu, Thomas Bachelot, et al.. (2016). BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-) advanced breast cancer (BC). Annals of Oncology. 27. vi68–vi68.
17.
Yao, James C., Do‐Youn Oh, Jiaming Qian, et al.. (2016). Efficacy and Safety of Everolimus in Advanced Nonfunctional Neuroendocrine Tumors (NET) of Lung or Gastrointestinal (GI) Origin: Findings From the Asian Subgroup Analysis of the RADIANT-4 Study. Annals of Oncology. 27. vii15–vii15.
18.
Buzzoni, Roberto, Gianfranco Delle Fave, Jonathan Strosberg, et al.. (2016). Impact of prior therapies on everolimus treatment in the subgroup of patients with advanced lung neuroendocrine tumors (NET) in the RADIANT-4 trial. Annals of Oncology. 27. vi138–vi138.
19.
Petersen, Irene, Ruth Gilbert, Stephen Evans, Antonia Ridolfi, & Irwin Nazareth. (2010). Oral antibiotic prescribing during pregnancy in primary care: UK population-based study. Journal of Antimicrobial Chemotherapy. 65(10). 2238–2246.
20.
Messahel, Boo, Richard D. Williams, Antonia Ridolfi, et al.. (2009). Allele loss at 16q defines poorer prognosis Wilms tumour irrespective of treatment approach in the UKW1–3 clinical trials: A Children’s Cancer and Leukaemia Group (CCLG) study. European Journal of Cancer. 45(5). 819–826.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Toby Silverman Breakdown of academic impact, for papers by Heinz Tüchler Breakdown of academic impact, for papers by Peter K. H. Lau Breakdown of academic impact, for papers by A.R. Abdul Razak Breakdown of academic impact, for papers by Jacques Raphael Breakdown of academic impact, for papers by Fabiano Sandrini Breakdown of academic impact, for papers by N.S. Russell Breakdown of academic impact, for papers by Agathe Bajard Breakdown of academic impact, for papers by Rafał Stec Breakdown of academic impact, for papers by Hélène Caillon